Immune and virological benefits of 10 years of permanent viral control with antiretroviral therapy

AIDS

Volumn 24, Issue 4, 2010, Pages 614-617

  Guihot, Amélie ^a,b   Tubiana, Roland ^b,c   Breton, Guillaume ^b   Marcelin, Anne Geneviève ^b   Samri, Assia ^a   Assoumou, Lambert ^c   Goncalves, Emilia ^a   Bricaire, François ^b   Costagliola, Dominique ^c   Calvez, Vincent ^b   Rouzioux, Christine ^d   Autran, Brigitte ^a   Katlama, Christine ^b,c   Carcelain, Guislaine ^a  

^a SORBONNE UNIVERSITÉ   (France)

^b PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

^c INSERM   (France)

^d HÔPITAL NECKER ENFANTS MALADES   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; ANTIGEN P24; GAMMA INTERFERON;

ARTICLE; CD4 LYMPHOCYTE COUNT; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MEMORY T LYMPHOCYTE; PRIORITY JOURNAL; VIRUS REPLICATION;

ADULT; AGED; ANTI-HIV AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; CD4 LYMPHOCYTE COUNT; CD4-POSITIVE T-LYMPHOCYTES; FEMALE; HIV INFECTIONS; HIV-1; HUMANS; MALE; MIDDLE AGED; VIRAL LOAD; VIRUS REPLICATION;

EID: 77649243563     PISSN: 02699370     EISSN: 14735571     Source Type: Journal    
DOI: 10.1097/QAD.0b013e32833556f3     Document Type: Article

References (18)

1. Viard JP, Burgard M, Hubert JB, Aaron L, Rabian C, Pertuiset N, et al. Impact of 5 years of maximally successful highly active antiretroviral therapy on CD4 cell count and HIV-1 DNA level. AIDS 2004; 18:45-49.
2. Moore RD, Keruly JC. CD4R cell count 6 years after commencement of highly active antiretroviral therapy in persons with sustained virologic suppression. Clin Infect Dis 2007; 44:441-446.
3. Le Moing V, Thiebaut R, Chene G, Sobel A, Massip P, Collin F, et al. Long-term evolution of CD4 count in patients with a plasma HIV RNA persistently 500 copies/ml during treatment with antiretroviral drugs. HIV Med. 2007; 8:156-163.
4. Mocroft A, Ledergerber B, Katlama C, Kirk O, Reiss P, d'Arminio Monforte A, et al. Decline in the AIDS and death rates in the EuroSIDA study: an observational study. Lancet 2003; 362:22-29.
5. Autran B, Carcelain G, Li TS, Blanc C, Mathez D, Tubiana R, et al. Positive effects of combined antiretroviral therapy on CD4R T cell homeostasis and function in advanced HIV disease. Science 1997; 277:112-116.
6. Li TS, Tubiana R, Katlama C, Calvez V, Ait Mohand H, Autran B. Long-lasting recovery in CD4 T-cell function and viral-load reduction after highly active antiretroviral therapy in advanced HIV-1 disease. Lancet 1998; 351:1682-1686.
7. Angel JB, Parato KG, Kumar A, Kravcik S, Badley AD, Fex C, et al. Progressive human immunodeficiency virus-specific immune recovery with prolonged viral suppression. J Infect Dis 2001; 183:546-554.
8. Lange CG, Lederman MM, Madero JS, Medvik K, Asaad R, Pacheko C, et al. Impact of suppression of viral replication by highly active antiretroviral therapy on immune function and phenotype in chronic HIV-1 infection. J Acquir Immune Defic Syndr 2002; 30:33-40.
9. Candotti D, Costagliola D, Joberty C, Bonduelle O, Rouzioux C, Autran B, Agut H. Status of long-term asymptomatic HIV-1 infection correlates with viral load but not with virus replication properties and cell tropism. French ALT Study Group. J Med Virol 1999; 58:256-263.
10. Yerly S, Kaiser L, Perneger TV, Cone RW, Opravil M, Chave JP, et al. Time of initiation of antiretroviral therapy: impact on HIV-1 viraemia. The Swiss HIV Cohort Study. AIDS 2000; 14:243-249.
11. Rouzioux C, Hubert JB, Burgard M, Deveau C, Goujard C, Bary M, et al. Early levels of HIV-1 DNA in peripheral blood mono-nuclear cells are predictive of disease progression independently of HIV-1 RNA levels and CD4R T cell counts. J Infect Dis 2005; 192:46-55.
12. Combadiere B, Boissonnas A, Carcelain G, Lefranc E, Samri A, Bricaire F, et al. Distinct time effects of vaccination on long-term proliferative and IFN-gamma-producing T cell memory to smallpox in humans. J Exp Med 2004; 199:1585-1593.
13. Samri A, Durier C, Urrutia A, Sanchez I, Gahery-Segard H, Imbart S, et al. Evaluation of the interlaboratory concordance in quantification of human immunodeficiency virus-specific T cells with a gamma interferon enzyme-linked immunospot assay. Clin Vaccine Immunol 2006; 13:684-697.
14. Gras L, Kesselring AM, Griffin JT, van Sighem AI, Fraser C, Ghani AC, et al. CD4 cell counts of 800 cells/ml or greater after 7 years of highly active antiretroviral therapy are feasible in most patients starting with 350 cells/ml or greater. J Acquir Immune Defic Syndr 2007; 45:183-192.
15. Kaufmann GR, Furrer H, Ledergerber B, Perrin L, Opravil M, Vernazza P, et al. Characteristics, determinants, and clinical relevance of CD4 T cell recovery to <500 cells/ml in HIV type 1-infected individuals receiving potent antiretroviral therapy. Clin Infect Dis. 2005;41:361-372.
16. Dragsted UB, Mocroft A, Vella S, Viard JP, Hansen AB, Panos G, et al. Predictors of immunological failure after initial response to highly active antiretroviral therapy in HIV-1-infected adults: a EuroSIDA study. J Infect Dis 2004; 190: 148-155. (Pubitemid 38858415)
17. Wood E, Hogg RS, Yip B, Quercia R, Harrigan PR, O'Shaugh-nessy MV, Montaner JS. Higher baseline levelsof plasma human immunodeficiency virus type 1 RNA are associated with increased mortality after initiation of triple-drug antiretroviral therapy. J Infect Dis 2003; 188:1421-1425.
18. Egger M, May M, Chene G, Phillips AN, Ledergerber B, Dabis F, et al. Prognosis of HIV-1-infected patients starting highly active antiretroviral therapy: a collaborative analysis of prospective studies. Lancet 2002; 360:119-129. (Pubitemid 34786200)